AC-101 RIPK2 Inhibitor: Novel Mechanism Enters Phase IIb Without Public Proof-of-Concept Efficacy Data

Accro Bioscience Doses First Patient in Phase IIb UC Study

Accro Bioscience has initiated its Phase IIb clinical trial for AC-101, a selective RIPK2 inhibitor, by dosing the first patient. The study targets patients with moderate-to-severe ulcerative colitis (UC) and is designed as a placebo-controlled, double-blind, multi-centre trial. It will compare two AC-101 dose groups against a placebo arm, with the primary endpoint being the proportion of patients achieving clinical remission at week 12. Exploratory metrics include histologic and long-term remission maintenance. This follows favorable safety and pharmacokinetic/pharmacodynamic profiles observed in earlier Phase I studies in Australia and China, and a completed Phase Ib proof-of-concept study in Chinese UC patients, whose results are expected at UEG Week 2026.

• Accro Bioscience has commenced its Phase IIb clinical trial for AC-101, a selective RIPK2 inhibitor, by dosing the first patient. The study is a placebo-controlled, double-blind, multi-centre trial designed to evaluate AC-101 in patients with moderate-to-severe ulcerative colitis, comparing two dose groups against a placebo arm.
• The primary objective of the Phase IIb study is to determine the proportion of patients achieving clinical remission at week 12. Additionally, the trial will assess exploratory metrics such as histologic remission and the maintenance of long-term remission, providing a comprehensive evaluation of AC-101's efficacy.
• AC-101's mechanism of action involves inhibiting receptor-interacting serine/threonine-protein kinase 2 (RIPK2), a crucial mediator in the nucleotide-binding oligomerisation domain (NOD) signalling pathway. Disruption of the NOD/RIPK2 pathway has been implicated in various inflammatory and autoimmune diseases, including inflammatory bowel disease, supporting AC-101's therapeutic potential for UC.

Designing the AC-101 Phase IIb Study for Moderate-to-Severe UC

Several pivotal and real-world trials across UC have employed varied designs — randomized controlled, observational, and registry-based — to evaluate induction and maintenance outcomes across biologic-naïve and biologic-experienced populations. The table below summarizes key study design parameters and endpoints from these trials.

Unlocking Ulcerative Colitis: The Role of RIPK2 Inhibition

Ulcerative colitis (UC) arises from a convergence of genetic predisposition, immune dysregulation, and epithelial barrier dysfunction. At the genetic level, genome-wide association studies have identified 200 independent risk loci for inflammatory bowel disease, with causal variants identified in genes including NOD2, ATG16L1, IRGM, IL23R, CARD9, RNF186, and PRDM1. European-derived IBD risk variants, including those at IL23R and NOD2, have been shown to confer risk across diverse populations, including Hispanics, underscoring the fundamental importance of these loci in UC pathogenesis. Variants within STAT3 have also been associated with inflammatory disease, with STAT3 identified as a key signaling molecule within the Th17 lymphocyte differentiation pathway — a T-helper cell subset increasingly implicated in UC alongside the traditionally recognized Th2-like immune profile.

At the molecular and cellular level, cytokine-driven signaling through the JAK-STAT pathway plays a central role in UC progression. Pro-inflammatory cytokines — including TNF-α, IL-1β, and IL-6 — are significantly elevated in UC tissue, while the anti-inflammatory cytokine IL-10 is correspondingly reduced. The IL-6–JAK1/2–STAT3 feed-forward loop is a particularly critical driver: RAD50, a DNA double-strand break sensor, directly interacts with STAT3 and inhibits its phosphorylation, thereby suppressing this loop. Deficiency of RAD50 in intestinal epithelial cells sensitizes mice to dextran sulfate sodium-induced colitis and promotes colitis-associated cancer development, with pharmacological STAT3 inhibition shown to relieve colitis in RAD50-deficient mice. Additionally, miRNA-101 expression is significantly elevated in UC tissue and correlates with IL-6 expression, suggesting involvement in JAK2-STAT3 pathway modulation. Leukocyte recruitment and adhesion — mediated through integrins such as α4β7 and their ligands including MAdCAM-1, alongside chemokine receptors including CCR9 and CXCR3 — further sustains the chronic mucosal inflammatory state.

Epithelial barrier integrity represents a third critical axis of UC pathogenesis. Disruption of intestinal tight junctions, mediated through a Ca²⁺/Ask1/MKK7/JNK2/c-Src signaling cascade, leads to barrier dysfunction and increased mucosal permeability. Structural weakening of the colonic mucus layer is an early event in UC, with major components including the mucin MUC2 significantly reduced (p<0.0001) in active UC — even in non-inflamed segments — alongside decreased numbers of sentinel goblet cells and attenuation of the goblet cell secretory response to microbial challenge. IL-18 signaling in intestinal epithelial cells further drives pathologic barrier breakdown by inhibiting goblet cell maturation through regulation of the transcriptional program instructing goblet cell development, with deletion of the IL-18 negative regulator IL-18bp resulting in severe colitis associated with loss of mature goblet cells. Together, these interconnected mechanisms — genetic susceptibility, cytokine-JAK-STAT signaling, and epithelial barrier failure — define the multifactorial pathogenesis of UC.

RIPK2 Inhibition: A New Frontier in Ulcerative Colitis Treatment

The initiation of Accro Bioscience's Phase IIb trial for AC-101 represents a pivotal moment for the development of novel therapies in ulcerative colitis. By targeting Receptor Interacting Protein Kinase 2 (RIPK2), AC-101 aims to modulate a critical signaling node implicated in inflammatory bowel disease (IBD) pathogenesis. Research indicates that RIPK2 mediates signals from NOD1 and NOD2, key cytosolic pattern recognition receptors that sense the intestinal microbiome and initiate immune responses. Dysregulation of this pathway is strongly associated with IBD, making RIPK2 an attractive, yet currently unaddressed, therapeutic target.

This trial could validate a new class of oral therapeutics for moderate-to-severe UC, offering a distinct mechanism of action compared to existing treatments. The potential for a first-in-class oral RIPK2 inhibitor could significantly reshape treatment paradigms, particularly for patients seeking non-injectable options or those who have not responded to conventional therapies. Accro Bioscience's strategic positioning as an early mover in this space could yield substantial market advantages if AC-101 proves successful.

However, the path forward is not without its challenges. While preclinical studies have shown promising results in ameliorating intestinal inflammation in various animal models and human cell lines, translating this efficacy to clinical remission in a diverse patient population remains the primary hurdle. The upcoming results from the Phase Ib proof-of-concept study, expected at UEG Week 2026, will provide crucial early insights. Furthermore, while Phase I data suggested a favorable safety profile, the long-term safety and tolerability of chronic RIPK2 inhibition in a larger patient cohort will be closely scrutinized. The emergence of other RIPK2 inhibitors in preclinical development also signals a future competitive landscape, underscoring the need for AC-101 to demonstrate clear differentiation and robust clinical benefits.